2023-506029-12-00
Recruiting
Phase 3
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)
AbbVie Deutschland GmbH & Co. KG80 sites in 6 countries755 target enrollmentStarted: March 20, 2024Last updated:
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 755
- Locations
- 80
- Primary Endpoint
- Pain freedom (defined as a reduction in headache severity from moderate/severe at baseline [predose] to no pain) at 2 hours after the DB dose for the first attack
Overview
Brief Summary
The primary objective of the trial is to evaluate the efficacy of a single dose of atogepant compared to placebo for the acute treatment of a single migraine attack. The first migraine attack during the DB treatment period will be used to assess efficacy of a single attack.
Study Design
- Allocation
- Not Applicable
- Primary Purpose
- Open Label Treatment Period
- Masking
- None
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects must voluntarily sign and date an informed consent, approved by an IEC/IRB, prior to the initiation of any screening or study-specific procedures.
- •History of migraines lasting between 4 to 72 hours when untreated or treated unsuccessfully and migraine episodes separated by at least 48 hours of headache pain freedom.
- •History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the 3 months prior to Visit 1/Screening per investigator judgment.
- •Female subjects who are not pregnant or breastfeeding, and are not planning to become pregnant or donate eggs during the study and for approximately 30 days after the last dose of study drug.
- •Female subjects (or individuals) of childbearing potential must have a negative serum pregnancy test at Visit 1/Screening and a negative urine pregnancy test at Visit 2/Randomization. Subjects with a borderline serum pregnancy test at Visit 1/Screening must have absence of clinical suspicion of pregnancy or other pathological causes of borderline results and a serum pregnancy test ≥3 days later to document continued lack of a positive result (unless prohibited by local requirements). Subjects with a urine pregnancy test at Visit 2/Randomization that is borderline or ambiguous must have a serum pregnancy test. In such cases, the subjects must be excluded from participation if the serum pregnancy result is positive.
- •Female subjects (or individuals) of childbearing potential must practice at least 1 protocol-specified method of birth control, from 30 days prior to Visit 2/Randomization until 30 days after the last dose of study drug. Female subjects of nonchildbearing potential do not need to use birth control.
- •Has used prescription or nonprescription medication for the acute treatment of migraine in the past.
- •Oral migraine medications used for prophylaxis on-label or off-label (e.g., topiramate, amitriptyline, beta blockers, flunarizine, venlafaxine, etc.), and injectable onabotulinum toxin A and other therapies used for migraine prevention are permitted provided that the treatment is stable for at least 3 months prior to Visit 2/Randomization and continues without change in dose throughout the study.
- •Subjects enrolling in the Triptan-Unsuitable substudy (applicable only after completion of enrollment in the main study) must meet all the inclusion criteria listed for the main study and must not meet any of the exclusion criteria listed for the main study. In addition, subjects must meet the following inclusion criterion: Subject must be ""triptan-unsuitable"" defined as meeting 1 of the 2 following criteria: -has a contraindication to triptans based upon local label and investigator judgment, irrespective of prior triptan use OR meets the following triptan failure definition for ≥2 different triptans: Currently uses a triptan or has used a triptan in the past and has not achieved pain relief (defined as the reduction of a moderate/severe migraine headache to a mild headache or no headache) at 2 hours postdose in ≥2 out of 4 attacks based upon subject interview and investigator judgment OR -Used a triptan in the past but no longer uses a triptan due to AEs based upon subject interview and investigator judgment.
- •Ability and willingness to read, understand, and complete study questionnaires and eDiary.
Exclusion Criteria
- •Subject has difficulty in distinguishing migraine headache from tension-type or other headaches per the investigator's judgment.
- •Positive result on the urine drug screen at Visit 1/Screening unless explained by allowed concomitant medication use (e.g., opioids prescribed for migraine pain, use of benzodiazepines for insomnia).
- •Positive result on the hepatitis B surface antigen or the anti-hepatitis C antibody testing at Visit 1/Screening.
- •Presence of other confounding pain syndromes, confounding psychiatric conditions, dementia, epilepsy and other significant neurological disorders other than migraine per investigator judgment.
- •Presence of chronic, nonheadache pain condition requiring daily pain medication.
- •Clinically significant cardiovascular, cerebrovascular, hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, psychiatric, or neurologic disease. -If there is a history of such disease but the condition has been stable for more than 6 months prior to Visit 1/Screening and is judged by the investigator as not likely to interfere with the subject's participation in the study, the subject may be included. -Subjects on dialysis for renal failure are not allowed to participate in the study.
- •Significant risk of self-harm, based on clinical interview or responses on the C-SSRS, or harm to others per the opinion of the investigator; subjects must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the last 6 months prior to Visit 1/Screening or Visit 2/Randomization.
- •History of malignancy in the 5 years prior to Visit 1/Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
- •History of any prior gastrointestinal conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of study drug. -Subjects with prior gastric bariatric interventions (e.g., Lap Band) which have been reversed may participate.
- •History of acute hepatitis within 6 months of Visit 1/Screening or any history of chronic liver disease (including nonalcoholic fatty liver disease, viral chronic hepatitis, and cirrhosis).
Outcomes
Primary Outcomes
Pain freedom (defined as a reduction in headache severity from moderate/severe at baseline [predose] to no pain) at 2 hours after the DB dose for the first attack
Pain freedom (defined as a reduction in headache severity from moderate/severe at baseline [predose] to no pain) at 2 hours after the DB dose for the first attack
Secondary Outcomes
- Absence of the MBS at 2 hours after the DB dose for the first attack (coprimary endpoint for China)
- Pain relief (defined as the reduction of a moderate/severe migraine headache at baseline [predose] to a mild headache or to no headache) at 2 hours after the DB dose for the first attack
- Sustained pain relief from 2 to 24 hours (defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours) after the DB dose for the first attack
- Sustained pain relief from 2 to 48 hours after the DB dose for the first attack
- Use of rescue medication within 24 hours after the DB dose for the first attack
- Ability to function normally at 2 hours after the DB dose for the first attack
- Sustained pain freedom from 2 to 24 hours (defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours) after the DB dose for the first attack
- Sustained pain freedom from 2 to 48 hours after the DB dose for the first attack
- Absence of photophobia at 2 hours after the DB dose for the first attack
- Absence of phonophobia at 2 hours after the DB dose for the first attack
- Pain freedom at 8 hours after the DB dose for the first attack
- Ability to function normally 8 hours after the DB dose for the first attack
- Pain relief at 1 hour after the DB dose for the first attack
- Absence of nausea at 2 hours after the DB dose for the first attack
- Pain relief at 30 minutes after the DB dose for the first attack
- Ability to function normally at 1 hour after the DB dose for the first attack
Investigators
Global Clinical Trials Helpdesk
Scientific
AbbVie Deutschland GmbH & Co. KG
Study Sites (80)
Loading locations...
Similar Trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine2024-512946-41-00AbbVie Deutschland GmbH & Co. KG247
Recruiting
Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine2022-501100-94-00Abbvie Deutschland GmbH & Co. KG151
Active, not recruiting
Phase 3
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine2023-507096-21-00AbbVie Deutschland GmbH & Co. KG382
Active, not recruiting
Phase 3
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine (TEMPLE)2022-501172-25-00Abbvie Deutschland GmbH & Co. KG475
Recruiting
Phase 1
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.NCT07272629Sanofi44